Conference
Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
Abstract
316
Background: Cabozantinib (cabo) is an oral multi-targeted tyrosine kinase inhibitor (TKI) with activity in mRCC. TKI toxicity, an indicator of adequate drug exposure, has been associated with clinical effectiveness for sunitinib, pazopanib, and axitinib. We explored whether cabo dose reductions (a surrogate for toxicity) were associated with improved clinical outcomes in mRCC. Methods: Using the CKCis database, we …
Authors
Graham J; Basappa NS; Ghosh S; Zhang H; Hansen AR; Lalani A-KA; Heng DYC; Soulieres D; Castonguay V; Kollmannsberger CK
Volume
40
Pagination
pp. 316-316
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2022
DOI
10.1200/jco.2022.40.6_suppl.316
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X